Clinical Trials Directory

Trials / Completed

CompletedNCT00971568

Urinary Biomarkers Characteristic to Interstitial Cystitis

Urinary Biomarkers Characteristic to Interstitial Cystitis- Proteomic Analysis of Urine

Status
Completed
Phase
Study type
Observational
Enrollment
15 (actual)
Sponsor
Corewell Health East · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a retrospective study of urine samples stored in the Beaumont BioBank for future research. The urine samples will be drawn from the urine back with patients previously diagnosed with severe interstitial cystitis (IC), mild IC and no IC. Interstitial Cystitis (IC) also known as Painful Bladder Syndrome (PBS) is a chronic inflammatory disease. It has an unknown etiology, symptoms which present to varying degrees, as well as an uncertain natural history. Diagnosis of IC is based on symptoms after excluding more common and dangerous pathologies.

Detailed description

Extensive research has been done to understand the multifactorial etiology as well as to help diagnose IC. Infectious, autoimmune and anatomic causes have been looked at with few usable results. Inflammatory cells and markers have been more productive. Recently we have shown in the rat model, that chemically induced inflammation, yields temporal increases in measurable cytokines and chemokines in the urine. Moreover, this was done by Multiplex analysis, using a multiple antigen bead assay (Luminex). Cytokines and chemokines, part of an organisms proteome, allow for looking at the function of a cell or organ at the time of the collection United States: Institutional Review Board. Urine is obtained non-invasively and yields significant information about urinary tract organs. The ability to find a biomarker or pattern of biomarker in the urine, diagnostic to a disease, offers significant advantages over serum or tissue diagnosis. We hope to identify patterns of inflammatory markers using proteomic analysis using the previously mentioned multiple antigen cassettes (Luminex) as well as identify possible new biomarkers using a Protein Chip SELDI--TOF (surface enhanced laser desorption ionisation-time of flight) mass spectrometer. The detection of patterns or new biomarkers has promise to help with diagnosis, treatment, and ultimately revealing the etiology and course of IC.

Conditions

Timeline

Start date
2009-09-01
Primary completion
2011-09-01
Completion
2011-09-01
First posted
2009-09-03
Last updated
2012-03-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00971568. Inclusion in this directory is not an endorsement.